Skip to content
Head to head

Viridian Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VRDN · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

VRDN +3.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
VRDNVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price29.96515.02
Change today-4.71%-1.08%
1-year return+1.7%+22.0%
Market cap$3.40B$130.58B
52-week range13.18 – 34.29412.27 – 568.67
Valuation
P/E (TTM)-7.7833.14
P/E percentile, own 5-yr range12th99th
P/B7.056.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.3215.32
Net profit (TTM)$-377.01M$3.88B
Revenue (TTM)$26.31M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-63.5%+11.8%
Gross margin23.6%85.5%
Operating margin-1781.4%33.1%
Net margin-1741.9%30.7%
Free cash flow (TTM)$-353.44M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership117.3%96.8%
Insider activity (12mo)38 buy / 11 sell28 buy / 22 sell
Short interest (% of float)15.0%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$40 (+35%)$624 (+21%)
StockVane view
StockVane Quant RatingC (45)C (68)
Company
Employees2526,400
Founded20061989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.